Detalhe da pesquisa
1.
Proof of pharmacology of Org 48775-0, a p38 MAP kinase inhibitor, in healthy volunteers.
Br J Clin Pharmacol
; 87(5): 2321-2332, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33201520
2.
Pharmacokinetics and Pharmacodynamics of the Dual Orexin Receptor Antagonist Daridorexant in Japanese and Caucasian Subjects.
J Clin Psychopharmacol
; 40(2): 157-166, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32134851
3.
The effect of food on the high clearance drug asenapine after sublingual administration to healthy male volunteers.
Eur J Clin Pharmacol
; 71(1): 65-74, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25552402
4.
Effects of sugammadex on activated partial thromboplastin time and prothrombin time in healthy subjects.
Int J Clin Pharmacol Ther
; 52(3): 227-36, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24447651
5.
Early stage development of the glycine-1 re-uptake inhibitor SCH 900435: central nervous system effects compared with placebo in healthy men.
Br J Clin Pharmacol
; 75(6): 1455-67, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23116363
6.
No clinically relevant interaction between sugammadex and aspirin on platelet aggregation and coagulation parameters.
Int J Clin Pharmacol Ther
; 51(12): 976-85, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24120718
7.
Sugammadex is not associated with QT/QTc prolongation: methodology aspects of an intravenous moxifloxacin-controlled thorough QT study.
Int J Clin Pharmacol Ther
; 50(8): 595-604, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22735462
8.
Sugammadex is cleared rapidly and primarily unchanged via renal excretion.
Biopharm Drug Dispos
; 32(3): 159-67, 2011 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-21370235
9.
Effect of absorption site on the pharmacokinetics of sublingual asenapine in healthy male subjects.
Biopharm Drug Dispos
; 31(5-6): 351-7, 2010 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-20549835
10.
Effects of sugammadex doses up to 32 mg/kg alone or in combination with rocuronium or vecuronium on QTc prolongation: a thorough QTc study.
Clin Drug Investig
; 30(9): 599-611, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-20568829
11.
Safety, tolerability and pharmacokinetics of sugammadex using single high doses (up to 96 mg/kg) in healthy adult subjects: a randomized, double-blind, crossover, placebo-controlled, single-centre study.
Clin Drug Investig
; 30(12): 867-74, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-20825252
12.
Assessment of Dermal Absorption of Aluminum from a Representative Antiperspirant Formulation Using a 26 Al Microtracer Approach.
Clin Transl Sci
; 11(6): 573-581, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30052317
13.
Pharmacological interactions between brivaracetam and ethanol in healthy males.
J Psychopharmacol
; 31(7): 915-926, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27649776
14.
Pharmacokinetic profile of nomegestrol acetate and 17ß-estradiol after multiple and single dosing in healthy women.
Contraception
; 87(2): 193-200, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22898360
15.
Effect of sugammadex on QT/QTc interval prolongation when combined with QTc-prolonging sevoflurane or propofol anaesthesia.
Clin Drug Investig
; 33(8): 545-51, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23824662
16.
Valproate reduces the glucuronidation of asenapine without affecting asenapine plasma concentrations.
J Clin Pharmacol
; 52(5): 757-65, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-21628604
17.
Asenapine Safety, Tolerability, and Pharmacokinetics After Single and Multiple Doses in Healthy Volunteers.
Clin Pharmacol Drug Dev
; 1(4): 131-43, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-27121455
18.
Flucloxacillin and diclofenac do not cause recurrence of neuromuscular blockade after reversal with sugammadex.
Clin Drug Investig
; 32(3): 203-12, 2012 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22201295
19.
Glycine transporter inhibitor attenuates the psychotomimetic effects of ketamine in healthy males: preliminary evidence.
Neuropsychopharmacology
; 37(4): 1036-46, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22113087
20.
Asenapine pharmacokinetics in hepatic and renal impairment.
Clin Pharmacokinet
; 50(7): 471-81, 2011 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-21651314